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ABSTRACT 
Objective: To develop and characterize indomethacin loaded-nanostructured lipid carriers (IND-NLCs) for topical ophthalmic delivery with 
different particle sizes and polymer coating to improve the mucoadhesive property on the ocular surface.  
Methods: Nanostructured lipid carriers (NLCs) with different solid lipids and surfactants were prepared by the high-pressure homogenization 
technique. The optimized IND-NLCs was coated with polyethylene glycol 400 (PEG). The physicochemical properties and entrapment efficacy (EE) 
were examined. In vitro release studies were investigated using the shake-flask method. Ex vivo mucoadhesive studies were assessed by the wash-
off test. In addition, the cytotoxicity was assessed by the short time exposure test.  
Results: IND-NLCs of ~300 and ~40 nm in diameter were successfully produced with a zeta potential of -30 mV and EE of 60–70 %. IND-NLCs 
prepared with Tween 80 as surfactant could be sterilized by autoclaving. The PEG coating of IND-NLCs did not affect either the particle size or EE. In 
vitro release showed a prolonged release for 360 min with a burst release of 50-60% occurring within 5 min. The smaller-sized IND-NLCs showed 
slightly faster release rates and better mucoadhesion to cornea compared to the larger IND-NLCs. PEG-coated IND-NLCs showed the highest 
mucoadhesion. In addition, IND-NLCs showed less cytotoxicity compared to IND alone.  
Conclusion: The small and PEG-coated NLCs represents a potentially useful carrier for safe delivery of indomethacin to the ocular surface with 
increased residence time. 
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Indomethacin (IND), a common non-steroidal anti-inflammatory 
drug (NSAID) in ocular therapeutics, is administered topically on the 
ocular surface for clinical management of conjunctivitis, anterior 
uveitis, and post-operative inflammation following cataract surgery 
[1]. Although it is stable at lower pH, IND possesses a low solubility 
of 3-5 mg/100 ml at pH 5.6 [2]. IND can be rendered soluble in 
aqueous buffers at pH 7.5-8.0 but with a risk of its hydrolysis into 5-
methoxy-2-methyl indolyl-3-acetic acid and 4-chlorobenzene acid 
[3]. Therefore, IND is formulated in the form of gels and suspensions 
to improve the solubility and stability [2, 3]. A polyethylene glycol 
(PEG)-based formulation of 0.1% indomethacin solution 
(Indocollyre®) is commercially available but it is known to exhibit 
poor bioavailability and cause irritation, superficial punctuate 
keratitis, and local pain [4]. Accordingly, nano-carriers drug delivery 
systems have been proposed as potential alternatives [5-8].  
Nano-carrier systems, in general, are able to encapsulate drug and 
thereby protect them against degradation. Also, nanoparticles can be 
mucoadhesive, and accordingly show increased their retention time 
on the ocular surface. These characteristics are suitable for 
enhanced stability and topical bioavailability of IND [9]. Among the 
nano-carrier systems, nanostructured lipid carriers (NLCs) possess 
unique characteristics that are promising for ophthalmic drug 
delivery. They have been developed to combine the advantages of 
other colloidal carriers but without their disadvantages [10]. For 
example, NLCs can be prepared using physiological lipids similar to 
nanoemulsions and liposomes, thus, providing less significant 
toxicity and acidic related inflammation problems compared to 
polymeric nanoparticles such as PLGA nanoparticles [11, 12]. 
Moreover, NLCs show better physical stability than nanoemulsions 
and liposomes by remaining in a solid state at room and body 
temperature. NLCs are composed of the imperfect crystalline 
structure of lipid matrix which formed by a mixture of solid and 
liquid lipid, and stabilized by surfactants. Therefore, the drug 
payload is increased, and expulsion of the drug during storage is 
avoided as compared to solid lipid nanoparticles (SLNs) [13]. 
A major challenge of topical ocular drug delivery is the poor 
bioavailability of the drug at the ocular surface and the anterior 
chamber [12]. Employing nano-carrier systems, the topical 
bioavailability can be improved by enhancing their residence time 
and corneal epithelial uptake [12]. Both parameters are strongly 
affected by the particle size and surface modification [11]. Although, 
Balguri et al. have recently reported increased bioavailability of IND 
to ocular tissues with IND-loaded NLCs [7], the effect of particle size 
and surface modifications have not been delineated.  
Therefore, the aim of this study was to develop IND-loaded NLCs 
(IND-NLCs) with different types of solid lipids and surfactants which 
improve the mucoadhesive property on the corneal surface. Surface-
modification of IND-NLCs with polyethylene glycol 400 (PEG) was 
also undertaken. Physicochemical properties of the developed IND-
NLCs were evaluated in terms of particle size, zeta potential, drug 
entrapment efficacy, and in vitro release study. The effect of the 
autoclaving method on the physicochemical stability of IND-NLCs 
was investigated. The retention of IND-NLCs on porcine cornea 
mucosa was determined using ex vivo mucoadhesive studies. In 
addition, in vitro cytotoxicity of the optimized IND-NLCs was 
investigated by the short time exposure test (STE) in primary 
porcine corneal epithelial (PCE) cells. 
MATERIALS AND METHODS 
Materials 
Gelucire 44/14 (lauryl macrogol-32 glyceride) and Compritol 888 
ATO (Compritol, glyceryl behenate) were kindly gifted by Gattefossé 
(Cedex, France). Lexol GT865 (medium chain triglyceride), cetyl 
palmitate and squalene were purchased from Namsiang trading 
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(Bangkok, Thailand). Tween 80 (Polysorbate 80) was acquired from 
AjexFinechem (Sydney, Australia). Emulmetik 900 was purchased 
from Lucas Meyer (Ludwigshafen, Germany). Indomethacin (Lot 
BCBK0293) was acquired from Sigma-Aldrich (China). AmiconUltra 
10K centrifugal filter was kindly gifted from Merck Millipore 
(Massachusetts, USA). Methanol and Acetonitrile used as HPLC 
solvent were purchased in HPLC grade quality from Lab Scan.  
Keratinocyte serum-free medium (K-SFM), bovine pituitary extract, 
recombinant human epidermal growth factor (EGF), and Gibco 
antibiotic-antimycotic (100x) were purchased from Invitrogen 
(California, USA). Hydrocortisone solution, human insulin solution, 
bovine serum albumin (BSA), bovine collagen type I, and human 
fibronectin were obtained from Sigma-Aldrich (Steinheim, Germany).  
Preparation of blank-NLCs and IND-NLCs  
IND-NLCs were prepared by a high-pressure homogenization 
technique. Briefly, the lipid phase contained 50 mg of IND, 2% 
(w/w) of squalene, 2% (w/w) of Emulmetik 900, 2% (w/w) of Lexol 
GT865, and 3% (w/w) of solid lipid was heated at 80 ˚C. Meanwhile, 
the aqueous phase consisting of 7% (w/w) of surfactant dissolved in 
distilled water was heated at 80 ˚C and slowly added to the oil phase. 
The obtained a primary emulsion was subjected to a high-speed 
homogenizer at 5000 rpm (T18, IKA, Staufen, Germany) for 1 min 
before subjected to a high-pressure homogenizer (M-110P, 
Microfluidics, Massachusetts, USA) applying 5 cycles at 1500 bar. 
The resulting hot o/w microemulsion was cooled at 25 ˚C, re-
solidification the lipid and forming the NLCs. Finally, the 
obtained NLCs was washed twice with a normal saline solution 
(NSS) using an ultrafiltration system (Amicon 8400, 
Massachusetts, USA) fitted with a molecular weight cut off 100 
kDa membrane to remove the excess components and 
unencapsulated IND. Blank-NLCs were prepared with the same 
method as described above without adding IND. NLCs were 
prepared by varying the type of solid lipid and surfactant 
namely; NLC1 (Compritol888 ATO and Tween 80); NLC2 (cetyl 
palmitate and Tween 80); NLC3 (Compritol888 ATO and Gelucire 
44/4); and NLC4 (cetyl palmitate and Gelucire 44/4). The 
selection of these variables was based on preliminary 
experiments. 
To prepare the mucoadhesive NLCs, NLC2 and IND-NLC2 were 
incubated with 0.1% (w/v) PEG 400 at a ratio of 1:1 and stirred at 
500 rpm for 30 min (C-MAG HS7, Guangzhou, China). The obtained 
polymer coated NLC2 (NLC2-PEG) and polymer-coated IND-NLC2 
(IND-NLC2-PEG) were washed as described above. All samples were 
prepared in triplicate. 
Sterilization by autoclaving 
Blank-NLCs and IND-NLCs were placed in a glass vial and sealed with 
rubber stoppers and aluminium caps. Then, the samples were 
sterilized by steam sterilization at 121 ˚C for 15 min at 2 bar. After the 
autoclaving process, the sterilized formulations were characterized 
the particle size, zeta potential, and drug remaining (%). 
Drug incorporation efficiency  
The content of IND incorporated into NLCs was determined by 
extraction method. Briefly, 100 µl of IND-NLCs was mixed with 900 µl of 
a mixture of 1 M HCl and methanol (1:90, v/v) and sonicated at 40% 
amplitude for 30 seconds by the ultrasonic probe (VCX130, Connecticut, 
USA). The sample was then centrifuged at 31,514 ×g for 10 min; then the 
supernatant was collected to determine the amount of IND using a 
modified high-performance liquid chromatography (HPLC) assay of 
Nováková L et al. [14]. The HPLC system (LC10AT, Shimadzu, Kyoto 
Japan) composed of an autosampler model SIL-10ADVP, a pump system 
model LC20-AT, and a UV/VIS detector model SPD-20A. Twenty µl of the 
sample was injected onto a Gemini 5u C18 110A (5 µm, 150 x 4.6 mm) 
which was kept at 25 ˚C. The mobile phase consisted of acetonitrile and 
0.2% (v/v) orthophosphoric acid at the volume ratio of 65:35 (v/v) was 
delivered at a flow rate of 1.2 ml/min. The UV detection was set at 270 
nm. IND was quantified from its peak area using calibration curve of IND 
established from the range of 1 to 50 µg/ml. The percentage of drug 
incorporation efficiency was calculated as [(Amount of extracted IND) × 
100]/(Initial amount of IND). 
Physico-chemical characterization of blank-NLCs and IND-NLCs 
The mean particle size and polydispersity index (PI) were determined by 
dynamic light scattering (DLS) with a ZetaPALS®analyzer (Brookhaven 
90Plus, New York, USA). This instrument was equipped with a 35 mW 
HeNe laser diode operating at 632.8 nm and a BI-200SM Goniometer 
connected to a BI-9010AT digital correlator. Samples were dispersed in 
DI water and run for 10 measurement cycles. The mean particle size and 
PI values were obtained by the auto measuring mode at a fixed angle of 
90 .̊ All samples were performed in triplicate. 
The zeta potential determined by measuring the particle electrophoretic 
mobility using the ZetaPAL® analyzer. The measurement was then 
carried out at 25 ˚C and angle of 14.8˚ to the incident light. The zeta 
potential was calculated based on the Smoluchowski equation. The 
measurement was performed for 5 cycles.  
The transmission electron microscope (TEM, Tecnai 12, Philips, 
USA) was used to examine the morphology of NLCs and IND-NLCs by 
negative staining method. Twenty µl of sample was deposited on a 
carbon-coated 300 mesh copper grid. Then, 10 µl of 0.5% (w/v) 
uranyl acetate in ethanol was dropped onto the grid. The excessive 
solvent was removed by Whatman no.1 filter paper and allowed to 
air-dry at room temperature. The dried sample was kept in a 
desiccator for further observation by TEM. 
In vitro release study 
The shake-flask method was employed to evaluate the dissolution 
profile of IND-NLCs formulations [15]. IND is a poorly water-soluble 
drug. Therefore, NSS (pH 5.5) contained 0.6% (v/v) Tween 80 was 
used as a dissolution medium to provide sink condition [16]. One ml 
of IND-NLCs (containing IND 0.4 mg) was mixed into 10 ml of 
dissolution medium and stirred at 200 rpm at 34±0.5 ˚C. An aliquot 
(500 µl) of the sample was taken at pre-determined time intervals of 
5, 30, 60, 120, 180, 240, and 360 min. The fresh medium was 
replaced immediately after sampling to maintain a constant volume. 
Samples were then centrifuged using 10K Amicon centrifugal filter 
at 17,508 ×g for 10 min. The filtrate was collected and mixed with 
mobile phase before performed on HPLC system as described above.  
Ex vivo mucoadhesive study 
The retention of IND-NLCs on the corneal surface was determined 
using an experimental setup previously described by Chaiyasan et al. 
[17]. Porcine eyes were obtained from the local slaughterhouse. The 
eyes were kept on the ice and kept moist with 1% (v/v) antibiotic 
solution until use (<8 h after death). The corneal tissue was cut out 
with a trephine (6 mm diameter) and mounted on a glass slide. IND-
NLCs (10 µl) was instilled on the cornea surface. Then, the tissue 
was exposed to a continuous stream of pH 5.5 NSS, 34 ˚C, at a flow 
rate of 0.3 ml/min for 5, 15, 30, and 60 min to induce shear stress 
mimicking blink action. Finally, the cornea tissue was collected and 
extracted to determine the IND-NLCs adhered to the tissue using 
HPLC method. The percentage of IND retained on the ocular surface 
calculated as [(Amount of extracted IND from cornea tissue) × 
100]/(Initial amount of IND-NLCs). 
Cytotoxicity of IND-NLCs in primary porcine corneal epithelial 
(PCE) cells 
Primary porcine corneal epithelial (PCE) cells from primary tissue 
explant technique were cultured as before [18, 19]. Briefly, the 
cornea was excised from the freshly isolated porcine eye, then 
sterilized with 1% (v/v) povidone-iodine for 5 min and rinsed thrice 
with PBS containing 1% (v/v) antibiotic-antimycotic. The explant 
was then placed epithelial side down onto 6-well tissue pre-coated 
culture plate with coating solution contained BSA, bovine collagen I, 
and human fibronectin. The explant was further cultured in K-SFM 
with supplements at 37 ˚C, in a humidified atmosphere containing 
5% CO2. The cornea was removed after 5 d, and the outgrowing cells 
were maintained in culture medium for 2-3 w. 
For several years, the method of choice to determine eye irritation 
potential was the Draize rabbit eye test. However, ethical considerations 
and the limited value of animal models including lack of reproducibility 
and overestimation of human response led to the development of 
alternative in vitro tests [20]. The short time exposure (STE) in vitro test 
is recommended for assessing eye irritation potential. The STE method is 
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straightforward to use and known to provide rapid results with the 
excellent predictive ability [21]. 
The cytotoxicity was assessed by the STE test using MTT assay as 
described by Kojima et al. but with some modifications [20]. The PCE 
cells were seeded on 96-well plate at 2 × 104 cells/well until reaching 
the semi-confluence (2-3 d). Then, the cells were exposed to 200 µl 
of IND-NLCs dispersed in PBS containing 5 and 0.05% (w/v) 
indomethacin for 5 min at room temperature. In addition, 5 and 
0.05% (w/v) IND solution, PBS, and 0.01% (w/v) sodium lauryl 
sulfate (SLS) were used as sample test, vehicle, and positive control, 
respectively. After exposure, the cells were washed with PBS twice, 
and 200 µl of methyl thiazol diphenyl-tetrazolium bromide (MTT) 
solution (0.5 mg/ml) in culture medium was added. After incubated 
for 2 h, MTT formazan was extracted with 200 µl of a mixture of 0.04 
N HCl in absolute isopropanol and DMSO (1:1, v/v) for 30 min. The 
absorbance was measured at 570 nm with a microplate reader 
(BioStack Ready, Vermont, USA). The relative cell viability was 
calculated comparing to the vehicle, then, category and rank 
classification was determined as described by Takahashi et al. [22]. 
RESULTS 
Physicochemical characteristics of blank-NLCs 
Table 1 shows the effect of different solid lipids, surfactants, and 
PEG coating on the physical characteristics of NLCs. NLC1 and NLC3, 
prepared with Compritol 888 ATO as solid lipid, showed a larger 
particle size of 307±29 and 144±8 nm, respectively. While preparing 
with cetyl palmitate, NLC2 and NLC4, reduced the particle size to 
39±4 and 34±1 nm, respectively.  
Moreover, NLC1 and NLC2, prepared with Tween 80 as a surfactant, 
demonstrated a larger particle size compared to those with Gelucire 
44/14, NLC3 and NLC4. The PI value of all formulations was less 
than 0.3 indicating a narrow size distribution. The hydrophilic 
coating with PEG, NLC2-PEG, affected neither the particle size nor 
zeta potential (p>0.05). 
 
Table 1: The components and physicochemical properties of NLCs 
Formulations Type of solid lipid: surfactant Mean size (nm)±SD 





Zeta potential (mV)±SD 
before autoclave  
(after autoclave) 
NLC1 Compritol: Tween 80 307±29 (261±10) 0.24±0.02 (0.31±0.03) -27±1 (-26±2) 
NLC2 cetyl palmitate: Tween 80 39±4 (40±3) 0.34±0.02 (0.21±0.08) -30±3 (-24±3) 
NLC2-PEG cetyl palmitate: Tween 80 42±2 (37±3) 0.16±0.05 (0.19±0.03) -28±1 (-31±2) 
NLC3 Compritol: Gelucire 44/14 144±8 (PS) 0.32±0.02 (PS) -30±6 (PS) 
NLC4 cetyl palmitate: Gelucire 44/14 34±1 (PS) 0.33±0.00 (PS) -28±5 (PS) 
SD: standard deviation for n=3; PS: phase separation 
 
The effects of sterilization by autoclaving on the physical 
characteristics of the blank-NLCs formulations were presented in 
table 1. The surfactant used in the formulations showed a critical 
effect on physical stability. NLC3 and NLC4, prepared by Gelucire 
44/14 could not autoclave as evidenced by the appearance of oil 
droplets, phase separation, and particle aggregation. However, 
NLC1, NLC2, and NLC2-PEG, prepared with Tween 80, provided 
stable NLCs. No significant difference in all the parameters was 
observed before and after autoclaving (p>0.05).  
Physicochemical characterization of IND-NLCs  
Table 2 showed the effect of different solid lipids, surfactants, and 
PEG coating on the physical characteristics of IND-NLCs. Compared 
to blank NLCs, IND-NLCs were slightly larger (p<0.05). However, 
IND loading showed no significant influence on the zeta potential 
and PI (p>0.05). The entrapment efficiency (EE) of IND-NLC1, IND-
NLC2, and IND-NLC2-PEG was 74.11±2.81, 65.09±3.16, and 
62.75±4.10, respectively.  
Table 2 also showed lack of any significant effect of sterilization on 
the physicochemical characteristics of all IND-NLCs formulations. 
The morphology examined by TEM was shown in fig. 1, both 
uncoated IND-NLC2, and PEG-coated IND-NLC2 exhibited 
spherical shape. The light grey border at the periphery (fig. 1B) 
was attributed to the presence of PEG coating around the particle 
surface. 
 
Table 2: Physicochemical characterizations of the optimized IND-NLCs 
Formulations Mean size (nm)±SD 





Zeta potential (mV)±SD 
before autoclave  
(after autoclave) 
Entrapment efficacy (%)±SD 
before autoclave  
(after autoclave) 
IND-NLC1 333±19 (261±10) 0.27±0.05 (0.31±0.03) -25±5 (-26±2) 74.11±2.81 (73.91±0.37) 
IND-NLC2 46±5 (40±3) 0.34±0.06 (0.21±0.08) -26±4 (-24±3) 65.09±3.16 (61.10±2.84) 
IND-NLC2-PEG 43±2 (40±3) 0.12±0.02 (0.21±0.08) -28±1 (-24±3) 62.75±4.10 (60.35±1.49) 
SD: standard deviation for n=3  
 
 
Fig. 1: TEM micrographs of (A) IND-NLC2 and (B) IND-NLC2-PEG 
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In vitro release study 
IND has a poor solubility of 0.83±0.04 µg/ml in NSS at ambient 
temperature. Therefore, 0.6% (w/v) Tween 80 was added to the NSS to 
provide a sink condition by increasing the solubility of IND to 
206.67±7.08 µg/ml. As shown in fig. 2, all formulations showed a 
biphasic release profile with a burst release during 5 min followed by a 
prolonged release up to 6 h following Higuchi’s model (Supplemental 
table 1). At the first 5 min, the cumulative release of IND from the IND-
NLC1 and IND-NLC2 was 48.24±3.15 and 56.14±9.86%, respectively. 
Then, they increased to 93.89±4.76 and 98.25±4.20%, respectively, after 
6 h. Moreover, in the case of IND-NLC2-PEG, the cumulative released of 
IND at 5 and 360 min was 47.64±0.92 and 80.04±4.72%, respectively. 
The results showed that the smaller particle size showed faster drug 
release rate than larger ones. Moreover, IND-NLC2-PEG showed slower 
drug release rate than uncoated ones (IND-NLC2). 
 
 
Fig. 2: In vitro release profiles of IND from IND-NLC1, IND-NLC2, 
and IND-NLC2-PEG in NSS with 0.6% (w/v) Tween 80 at 34 °C. 
Error bars represent standard deviation for n=3 
 
Ex vivo mucoadhesion test  
The percentage of IND remaining on the porcine cornea tissue after 
installation was depicted in fig. 3. After 5 min of fluid flow, cornea 
tissue instilled with IND solutions showed ~28% remaining while 
those instilled with IND-NLC1, IND-NLC2, and IND-NLC2-PEG 
showed ~59%, ~70%, and ~73% remaining, respectively. 
Moreover, nearly 100% loss occurred after 60 min of fluid flow 
when instilled with IND solutions, IND-NLC1, and IND-NLC2. On the 
other hand, IND-NLC2-PEG showed ~8% remaining after 60 min of 
continuous fluid flow. These results indicated that small NLCs (IND-
NLC2) showed higher mucoadhesive property than larger NLCs 
(IND-NLC1), especially, NLCs coating with PEG provided the highest 
mucoadhesiveness on ocular surface.  
 
 
Fig. 3: The percentage of IND remaining on porcine cornea 
tissue after a steady flow of NSS for 60 min. Error bars 
represent standard deviation for n=3 
 
Cytotoxicity of IND-NLCs  
As shown in table 3, exposure of PCE cells to IND-NLC2 and IND-
NLC2-PEG contained 0.5 and 5% IND, showed cell viability of>70%. 
Based on Takahashi et al., they could be classified as non-irritants 
[22]. On the other hand, 5% of IND-solutions and 0.01% SLS 
(positive control) exhibited cell viability (%) of 56.16±4.23 and 
59.69±3.96, respectively, confirming their irritation potential [22]. 
  
Table 3: Summary of short time exposure (STE) tests performed by MTT assay 
Sample IND (% w/v) Cell viability (%) (mean±SD) STE classificationa 
IND-NLC2 5 72.47±1.51 non-irritant 
 0.05 92.76±2.54 non-irritant 
IND-NLC2-PEG 5 73.63±1.05 non-irritant 
 0.05 91.24±4.81 non-irritant 
IND-solution 5 56.16±4.23 irritant 
 0.05 72.56±2.47 non-irritant 
SLS 0.01 59.69±3.96 irritant 
aEye irritation potential classification STE; Cell viability>70% is classified as non-irritant [21], SD: standard deviation for n=3  
 
DISCUSSION 
Topical NSAIDs frequently produce side effects and adverse reactions 
ranging from burning sensation, stinging, and to minor signs of ocular 
irritation [23]. Stroobant et al., reported several formulations of 
topical NSAIDs eye drops to impact the rabbit corneal epithelial 
adversely [24]. Hence, safe and effective formulations of topical 
NSAIDs remain an unmet need in ophthalmic therapeutics [25]. In this 
study, NLCs was employed as a drug carrier with the goal not only to 
overcome the adverse effects of topical NSAIDs but also to provide 
enhanced bioavailability, which could be improved by enhanced 
residence time on the cornea surface. 
IND-NLCs were successfully prepared by a high-pressure 
homogenization technique. This technique has been used extensively 
because of its advantages including reliability, ease of scale-up, and 
cost-effectiveness [26]. The particles produced were found to be 
suitable for ophthalmic applications with size ranging ∼40-300 nm. 
In addition, all INC-NLCs formulations exhibited a high zeta potential 
of -30 mV, which would provide a long-term physical stability. The 
negative charge could be attributed to the presence of medium chain 
triglyceride carboxylic group on the particle surface [27].  
In agreement with previous reports, the number of the fatty acid 
side chain on solid lipid and surfactant had a significant effect on the 
particle size of NLCs [28, 29]. In case of solid lipid type, NLCs 
prepared with Compritol 888 ATO (fatty acid side chains, C22) 
resulted in larger particle size than NLCs prepared with cetyl 
palmitate (fatty acid side chains, C16). Similarly, NLCs stabilized with 
Tween 80 (fatty acid side chains, C18), showed larger size than NLCs 
stabilized with Gelucire 44/14 (fatty acid side chains, C12). These 
could be attributed to the solid lipid, and surfactant with long fatty 
acid side chain commonly forms larger particle size. 
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The type of liquid lipid, solid lipid and surfactant all play an 
important role in incorporating a drug into NLCs [30]. In general, the 
incorporation of a liquid lipid consisting of a medium chain 
triglyceride along with a solid lipid consisting of a long chain 
triglyceride is known to increase the loading capacity and also 
enable controlled release [31]. Therefore, Lexol GT865 (medium 
chain triglyceride, C8 and C10) was chosen as a liquid lipid in all 
formulations [32]. As expected, IND-NLC1 prepared with Compritol 
888 ATO (fatty acid side chains, C22) showed higher EE compared to 
IND-NLC2 prepared with cetyl palmitate (fatty acid side chains, C16). 
This could be explained by increasing the space created between the 
solid fatty acid chain and the medium chain triglyceride, allowing 
more drug to be accommodated [33, 34]. In addition, the complete 
IND incorporation was confirmed by polarized light microscopy 
(data not shown). 
Sterilization of ophthalmic formulation is critical for topical 
application as microbial contamination should be prevented [35, 
36]. One of the strongest advantages of these NLCs is possible to 
sterile by an autoclaving method which is a commonly used and 
reliable technique. Taken together, the components for the 
preparation of NLCs must withstand the conditions of sterilization. 
As shown in table 1, the physicochemical properties of NLCs were 
not affected by the type of solid/liquid lipids and polymer after 
autoclaving. However, the type of surfactant appears to have a 
profound influence. We found that NLCs prepared with Tween 80 
withstood the sterilization by autoclaving in agreement with 
previous reports [37, 36]. The phenomena could be explained by the 
difference in the fatty acid side chain of the surfactants. During 
autoclaving, the lipid matrix melts and then recrystallizes again 
during cooling at room temperature. As Tween 80 has a side chain of 
18 carbon atoms, its long chain could have more chance to penetrate 
to the solid lipid phase, consequently lead to more compact and 
stronger particles. Gelucire 44/14, on the other hand, is composed of 
12-carbon short side chain and hence it would be harder to stabilize 
the particles leading to phase separation.  
Depending on the production process and especially different lipid 
blended, the different type of NLCs are obtained [26]. Due to the 
ratio of solid lipid/oil, 5/4, used in developed NLCs formulations, we 
assumed that the multiple types of NLCs would be achieved [31]. 
According to Müller et al., high levels of the oil can exceed their 
solubility in the solid lipid leading to precipitation as tiny oil nano 
compartments within the lipid matrix during the cooling process 
[26]. These oil nano compartments can contain a higher amount of 
IND. However, the release of the drug would still be controlled by 
the surrounding solid lipid barrier. These observations help explain 
in vitro release data as discussed below. 
As shown in fig. 2, we found biphasic IND release, with the burst 
phase contributing up to 50%. This burst release arguably would be 
beneficial since therapeutic drug levels can be reached after the 
administration [39]. The burst release of IND could be attributed to 
the re-distribution of IND during preparation process [26]. During 
hot homogenization, heating leads to an increased IND solubility in 
the water phase, thus, some drug partition from the melt lipid 
droplet to the water phase. However, during cooling, the solubility of 
the drug in water phase decreases leading to a re-partitioning of the 
drugs into the lipid phase. At the same time, the lipid phase starts to 
solidify and thus, the drugs are not accessible for the re-partitioning. 
Therefore, some of IND are accumulated at the matrix surface 
leading to the burst release characteristics.  
However, after the burst release, the release profile could be the best 
fit to the Higuchi square root model. This indicates that IND released 
from the NLCs in the second phase occurs by a diffusion-controlled 
mechanism from oil nano-compartment to the matrix for 
subsequent release to the medium. Also, the release of IND-NLC2 
coated with PEG, an uncharged hydrophilic polymer, is slightly 
reduced possibly due to the presence of the polymer in the outer 
regions of the particles.  
IND-NLCs showed grater adhesion on the porcine cornea tissue 
compared to IND solutions. It was found that the small IND-NLC2 
(~40 nm) showed higher retention than large IND-NLC1 (~300 nm). 
Li et al., had suggested that NLCs with a particle size of 100 nm could 
be easily inserted into the branching sugar chains of mucin and 
thereby led to a stronger mucoadhesive property, compared to NLCs 
with a particle size of 200 and 300 nm [11]. This could be attributed 
to the small particle size exhibits more surface area to adhere on the 
corneal surfacea, In addition, surface modification of NLCs by 
coating with PEG could further improve ocular mucoadhesion. As 
Kashanian et al., noted that NLCs coating with PEG leads to an 
increment of nanoparticles penetration through mucus layer of the 
ocular surface possibly via PEG interpenetrating the mucus network 
aided by hydrogen bonding [40-42]. 
As a first step, we assessed the in vitro cytotoxicity of IND-NLCs in 
PCE cells following STE test protocol recommended as a potential 
alternative method for the assessment of ocular irritation in place of 
animal testing [20]. We have found the two candidates NLCs 
formulations (IND-NLC2 and IND-NLC2-PEG) caused much less 
toxicity compared to IND in solutions. Interestingly, IND 
nanoparticles eye drops (containing 0.5% indomethacin) prepared 
using zirconia beads and Bead Smash 12, the particle size of 76±59 
nm, are much tolerated better by a human cornea epithelial cell line 
(HCE-T) and rat corneal epithelial cells than commercial IND eye 
drops [5]. This could be explained by its sustained release, which 
lowers the risk of locally high concentrations, decreasing the direct 
cells stimulation leads to minimize local irritation. Therefore, the 
releasing of IND from IND-NLCs to the cells provided a less toxicity 
compared to direct cells stimulation form IND-solutions. Moreover, 
the nanoparticle formulations may decrease in the drug dose via an 
increase in bioavailability, thus resulting in a reduction in drug 
toxicity. Furthermore, IND-NLCs can be easily developed avoiding 
the use of organic solvents, and the selection of Tween 80 as a 
surfactant was reported to be non-irritating to the rabbit eye up to a 
concentration of 10% and has been used in a number of marketed 
ophthalmic solution eye drop [43]. 
CONCLUSION 
IND-NLCs were successfully prepared by a high-pressure 
homogenization technique to overcome the problems of IND on the 
topical ophthalmic formulations. Additionally, NLCs are solid at 
room and body temperature which can be formulated as nano-
dispersions in liquid dosage forms. Therefore, they can be 
administered as an eye drop to avoid blurred vision and comfortable 
due to the nano size. The developed NLCs with Tween 80 could be 
sterile by the autoclaving method. The particle size of ~300 and ~40 
nm was produced depending on the type of solid lipid. Small and 
PEG-coated IND-NLCs enhance the mucoadhesion on the freshly 
porcine cornea which expected to improve ocular bioavailability. In 
addition, the developed NLCs showed less cytotoxicity to PCE cells 
compared to IND solution. Therefore, these nanoparticles will show 
increased effectiveness in treating ocular inflammation requiring the 
long-term application of eye drop with less toxicity. In conclusion, 
our findings suggest that NLCs with small size and PEG-coating 
demonstrate a promising approach for ocular drug delivery. 
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